View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAceragen 과거 순이익 실적과거 기준 점검 0/6Aceragen은 연평균 28.9%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 36.2%의 비율로 증가했습니다. 매출은 연평균 34.1%의 비율로 증가했습니다.핵심 정보28.94%순이익 성장률40.27%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률34.15%자기자본이익률-71.58%순이익률-559.86%최근 순이익 업데이트31 Mar 2023최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesPrice Target Changed • Aug 15Price target decreased by 88% to US$17.00Down from US$142, the current price target is provided by 1 analyst. New target price is 3,909% above last closing price of US$0.42. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$2.18 next year compared to a net loss per share of US$7.18 last year.공시 • May 31Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingAceragen, Inc. announced that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has until July 24, 2023 to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 calendar days from the Form 10-Q’s original due date, or November 20, 2023, to regain compliance. If the Company is unable to make such filings by July 24, 2023, the Company intends to submit to Nasdaq a plan to regain compliance.공시 • May 16Aceragen, Inc. announced delayed 10-Q filingOn 05/15/2023, Aceragen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • May 06Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial OfficerAceragen, Inc. announced that effective as of the Effective Date, John Kirby no longer serves as the Company’s Chief Financial Officer or is employed by the Company. Mr. Kirby is entitled to certain payments and post-termination benefits as set forth in his employment continuation and retention bonus letter agreement and his Severance and Change of Control Agreement with the Company, each as described on pages 80, 88 and 89 of the 2022 Form 10-K.공시 • Feb 07Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra StudyAceragen, Inc. announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and has recommended the TERRA study continue without modification. The DMC review was a planned meeting held in order to monitor the safety of the seriously ill subjects participating in the TERRA study. Aceragen has executed an ~$50 million development partnership with the Department of Defense’s Defense Threat Reduction Agency (“DTRA”) to investigate ACG-701 as a potential medical countermeasure for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen. This program is centered around a Phase 2 trial, the TERRA study (NCT05105035), which is a randomized double-blind, placebo-controlled trial conducted in hospitalized melioidosis patients. TERRA was initiated in May 2022 and continues to actively enroll patients with a data read-out expected in the fourth quarter of 2023.공시 • Feb 04Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023Aceragen, Inc. announced that on February 3, 2023, Bryant D. Lim will be leaving his role as Senior Vice President, Chief Business Officer and General Counsel of the Company, effective February 17, 2023, to pursue another opportunity.Seeking Alpha • Sep 28Idera Pharmaceuticals completes acquisition of AceragenIdera Pharmaceuticals (NASDAQ:IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction. The acquisition, not subject to the approval of Idera stockholders, was unanimously approved by the board of both the companies. The combined cash of the two companies is expected help in funding the advancement of Aceragen's pipeline through 2023. Idera's former CEO, Vincent Milano, has been named board chair. Aceragen's former CEO, John Taylor, succeeds Milano. Additionally, Aceragen's former chief medical officer, Carl Kraus, will serve in that role for Idera. Also, Aceragen's former COO, Daniel Salain, will serve in that role for Idera. And, Andy Jordan, Aceragen's former CFO has been appointed chief strategy officer for Idera. IDRA shares were trading +19.85% post-market. Source: Press Release분석 기사 • Aug 24We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.분석 기사 • May 11We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.Recent Insider Transactions • Jun 22Senior VP & COO recently bought US$60k worth of stockOn the 18th of June, Daniel Soland bought around 50k shares on-market at roughly US$1.19 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$101k. Daniel has been a buyer over the last 12 months, purchasing a net total of US$98k worth in shares.Recent Insider Transactions • Jun 04Independent Chairman recently bought US$101k worth of stockOn the 1st of June, Michael Dougherty bought around 85k shares on-market at roughly US$1.19 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.Executive Departure • May 30Senior VP & Chief Medical Officer has left the companyOn the 28th of May, Elizabeth Tarka's tenure as Senior VP & Chief Medical Officer ended after 1.8 years in the role. As of March 2021, Elizabeth personally held only 13.24k shares (US$17k worth at the time). Elizabeth is the only executive to leave the company over the last 12 months.Price Target Changed • Mar 16Price target increased to US$8.60Up from US$7.83, the current price target is an average from 4 analysts. New target price is 84% above last closing price of US$4.68. Stock is up 337% over the past year.분석 기사 • Mar 07Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Jan 31When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?With the business potentially at an important milestone, we thought we'd take a closer look at Idera Pharmaceuticals...Is New 90 Day High Low • Jan 20New 90-day high: US$5.40The company is up 158% from its price of US$2.09 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.분석 기사 • Dec 27Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?If you want to know who really controls Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ), then you'll have to look at the...분석 기사 • Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)We'd be surprised if Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ) shareholders haven't noticed that the President...Recent Insider Transactions • Dec 26President recently sold US$161k worth of stockOn the 22nd of December, Vincent Milano sold around 37k shares on-market at roughly US$4.32 per share. This was the largest sale by an insider in the last 3 months. This was Vincent's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Dec 26President notifies of intention to sell stockVincent Milano intends to sell roughly 37.17k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of December. If the sale is conducted around the recent share price of US$4.41, it would amount to US$164k. For the year to December 2019, Vincent's total compensation was 45% salary and 55% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Vincent has owned 61.25k shares directly. This was the only transaction from an insider over the last 12 months.분석 기사 • Nov 25We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, Idera Pharmaceuticals...Is New 90 Day High Low • Nov 19New 90-day high: US$3.33The company is up 84% from its price of US$1.81 on 20 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Analyst Estimate Surprise Post Earnings • Nov 03Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 168%.Is New 90 Day High Low • Oct 29New 90-day high: US$2.69The company is up 35% from its price of US$1.99 on 30 July 2020. The American market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Sep 19New 90-day high: US$2.68The company is up 41% from its price of US$1.90 on 19 June 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.매출 및 비용 세부 내역Aceragen가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:ACGN 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 237-4115031 Dec 225-2312030 Sep 220-1691630 Jun 220-1891031 Mar 220-209-731 Dec 2109710030 Sep 2102411530 Jun 2109112531 Mar 210-8112931 Dec 200-113122530 Sep 200-87122230 Jun 200-7813931 Mar 201-6513931 Dec 191-85123530 Sep 192-45131030 Jun 192-4614531 Mar 190-51151331 Dec 181-60154230 Sep 181-63161930 Jun 181-66152431 Mar 181-71152531 Dec 171-66162630 Sep 1716-50152630 Jun 1716-49152531 Mar 1716-41152531 Dec 1616-38152430 Sep 161-51152230 Jun 161-50152131 Mar 161-49152231 Dec 150-49152030 Sep 150-49151930 Jun 150-47142031 Mar 150-42131731 Dec 140-39111630 Sep 140-34101430 Jun 140-2991131 Mar 140-268931 Dec 130-218730 Sep 130-217730 Jun 130-216831 Mar 130-196931 Dec 120-2261330 Sep 120-26712양질의 수익: ACGN 은(는) 현재 수익성이 없습니다.이익 마진 증가: ACGN는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ACGN는 수익성이 없지만 지난 5년 동안 연평균 28.9%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ACGN의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ACGN은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ACGN는 현재 수익성이 없으므로 자본 수익률이 음수(-71.58%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/08/23 08:55종가2023/08/21 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Aceragen, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael UlzBairdMichael KingCitizens JMP Securities, LLCMatthew BannonJ.P. Morgan5명의 분석가 더 보기
Price Target Changed • Aug 15Price target decreased by 88% to US$17.00Down from US$142, the current price target is provided by 1 analyst. New target price is 3,909% above last closing price of US$0.42. Stock is down 94% over the past year. The company is forecast to post a net loss per share of US$2.18 next year compared to a net loss per share of US$7.18 last year.
공시 • May 31Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingAceragen, Inc. announced that on May 24, 2023, the Company received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company had not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The Nasdaq notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Market. The Company has until July 24, 2023 to submit to Nasdaq a plan to regain compliance. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 calendar days from the Form 10-Q’s original due date, or November 20, 2023, to regain compliance. If the Company is unable to make such filings by July 24, 2023, the Company intends to submit to Nasdaq a plan to regain compliance.
공시 • May 16Aceragen, Inc. announced delayed 10-Q filingOn 05/15/2023, Aceragen, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • May 06Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial OfficerAceragen, Inc. announced that effective as of the Effective Date, John Kirby no longer serves as the Company’s Chief Financial Officer or is employed by the Company. Mr. Kirby is entitled to certain payments and post-termination benefits as set forth in his employment continuation and retention bonus letter agreement and his Severance and Change of Control Agreement with the Company, each as described on pages 80, 88 and 89 of the 2022 Form 10-K.
공시 • Feb 07Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra StudyAceragen, Inc. announced the recommendation of its independent Data Monitoring Committee (DMC) in regard to the on-going TERRA Phase 2 study of ACG-701 in patients with melioidosis. The DMC is responsible for providing oversight of safety and efficacy for this study and has recommended the TERRA study continue without modification. The DMC review was a planned meeting held in order to monitor the safety of the seriously ill subjects participating in the TERRA study. Aceragen has executed an ~$50 million development partnership with the Department of Defense’s Defense Threat Reduction Agency (“DTRA”) to investigate ACG-701 as a potential medical countermeasure for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen. This program is centered around a Phase 2 trial, the TERRA study (NCT05105035), which is a randomized double-blind, placebo-controlled trial conducted in hospitalized melioidosis patients. TERRA was initiated in May 2022 and continues to actively enroll patients with a data read-out expected in the fourth quarter of 2023.
공시 • Feb 04Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023Aceragen, Inc. announced that on February 3, 2023, Bryant D. Lim will be leaving his role as Senior Vice President, Chief Business Officer and General Counsel of the Company, effective February 17, 2023, to pursue another opportunity.
Seeking Alpha • Sep 28Idera Pharmaceuticals completes acquisition of AceragenIdera Pharmaceuticals (NASDAQ:IDRA) has completed the acquisition of privately-held biotechnology company Aceragen in a stock-for-stock transaction. The acquisition, not subject to the approval of Idera stockholders, was unanimously approved by the board of both the companies. The combined cash of the two companies is expected help in funding the advancement of Aceragen's pipeline through 2023. Idera's former CEO, Vincent Milano, has been named board chair. Aceragen's former CEO, John Taylor, succeeds Milano. Additionally, Aceragen's former chief medical officer, Carl Kraus, will serve in that role for Idera. Also, Aceragen's former COO, Daniel Salain, will serve in that role for Idera. And, Andy Jordan, Aceragen's former CFO has been appointed chief strategy officer for Idera. IDRA shares were trading +19.85% post-market. Source: Press Release
분석 기사 • Aug 24We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Board Change • Jun 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
분석 기사 • May 11We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth CarefullyJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Board Change • May 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. Independent Chairman Mike Dougherty was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.
Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.
Director Overboarding • Aug 03Director Vincent Milano has joined 3rd company boardPresident, CEO & Director Vincent Milano has been appointed to the board of BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX). Milano now sits on a total of 3 company boards. With 3 board positions including the role of CEO at Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), the director is at risk of having too many board obligations according to the Simply Wall St Risk Model.
Recent Insider Transactions • Jun 22Senior VP & COO recently bought US$60k worth of stockOn the 18th of June, Daniel Soland bought around 50k shares on-market at roughly US$1.19 per share. In the last 3 months, there was an even bigger purchase from another insider worth US$101k. Daniel has been a buyer over the last 12 months, purchasing a net total of US$98k worth in shares.
Recent Insider Transactions • Jun 04Independent Chairman recently bought US$101k worth of stockOn the 1st of June, Michael Dougherty bought around 85k shares on-market at roughly US$1.19 per share. This was the largest purchase by an insider in the last 3 months. This was Michael's only on-market trade for the last 12 months.
Executive Departure • May 30Senior VP & Chief Medical Officer has left the companyOn the 28th of May, Elizabeth Tarka's tenure as Senior VP & Chief Medical Officer ended after 1.8 years in the role. As of March 2021, Elizabeth personally held only 13.24k shares (US$17k worth at the time). Elizabeth is the only executive to leave the company over the last 12 months.
Price Target Changed • Mar 16Price target increased to US$8.60Up from US$7.83, the current price target is an average from 4 analysts. New target price is 84% above last closing price of US$4.68. Stock is up 337% over the past year.
분석 기사 • Mar 07Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Jan 31When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?With the business potentially at an important milestone, we thought we'd take a closer look at Idera Pharmaceuticals...
Is New 90 Day High Low • Jan 20New 90-day high: US$5.40The company is up 158% from its price of US$2.09 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
분석 기사 • Dec 27Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?If you want to know who really controls Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ), then you'll have to look at the...
분석 기사 • Dec 27Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)We'd be surprised if Idera Pharmaceuticals, Inc. ( NASDAQ:IDRA ) shareholders haven't noticed that the President...
Recent Insider Transactions • Dec 26President recently sold US$161k worth of stockOn the 22nd of December, Vincent Milano sold around 37k shares on-market at roughly US$4.32 per share. This was the largest sale by an insider in the last 3 months. This was Vincent's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Dec 26President notifies of intention to sell stockVincent Milano intends to sell roughly 37.17k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of December. If the sale is conducted around the recent share price of US$4.41, it would amount to US$164k. For the year to December 2019, Vincent's total compensation was 45% salary and 55% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since March 2020, Vincent has owned 61.25k shares directly. This was the only transaction from an insider over the last 12 months.
분석 기사 • Nov 25We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, Idera Pharmaceuticals...
Is New 90 Day High Low • Nov 19New 90-day high: US$3.33The company is up 84% from its price of US$1.81 on 20 August 2020. The American market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Analyst Estimate Surprise Post Earnings • Nov 03Earnings beat expectationsRevenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 168%.
Is New 90 Day High Low • Oct 29New 90-day high: US$2.69The company is up 35% from its price of US$1.99 on 30 July 2020. The American market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Sep 19New 90-day high: US$2.68The company is up 41% from its price of US$1.90 on 19 June 2020. The American market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.